Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
Presently, intravenous bisphosphonates are routinely used every 3 to 4 weeks in patients
with osseous metastases from breast cancer. However, there is no data addressing the effects
of intravenous bisphosphonate therapy on the results of bone scan imaging. Therefore, the
first step in the collaboration between MSKCC Breast Cancer Medicine Service and Nuclear
Medicine Service is to define whether or not intravenous bisphosphonate therapy affects the
results of bone imaging with the standard technetium, Tc-99m MDP. Women receiving
intravenous bisphosphonate therapy for breast cancer metastases involving bone at MSKCC are
eligible for this diagnostic clinical is no therapeutic intent in this study.
Bone Scan performed before intravenous bisphosphonate therapy (baseline as clinically
indicated). Ideally, the bone scan will be performed immediately before to, bisphosphonate
Zoledronic acid, intravenous bisphosphonate therapy (as clinically indicated)
Bone Scan performed within 1 day after intravenous bisphosphonate therapy (study test).
Number of lesions seen in the baseline and study test will be counted and compared for
changes in imaging results induced by intravenous bisphosphonate therapy.
The number of lesions detected by bone scan pre and post therapy will be recorded and the
difference will be calculated.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic
Evaluate whether routine clinical use of intravenous zoledronic acid therapy affects technetium methylidene diphosphonate (Tc-99 MDP) uptake in bone metastases.
Ravinder Grewal, MD
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|